Immune cells armed with antibody take aim at stubborn leukemia
NCT ID NCT07270978
First seen Dec 24, 2025
Summary
This early-phase trial tests a new approach for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer after treatment. The therapy uses the patient's own blood cells, armed with a special antibody to target cancer cells. Up to 23 participants will receive weekly infusions followed by standard drugs, to see if it is safe and helps clear the remaining disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD33Bi-armed fresh peripheral blood mononuclear cells (CD33 FPBMC)
What this could lead to
If successful, this could offer a new way to eliminate remaining cancer cells in patients with AML or MDS who still have detectable disease after standard treatment.
What could go wrong
This is a very early Phase 1 trial with only 23 participants, so safety and dosing are still being figured out. It may not work for everyone, and side effects from the cell infusions or combination drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.